Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

据证券之星公开数据整理，近期康为世纪（688426）发布2025年中报。截至本报告期末，公司营业总收 入8711.87万元，同比上升29.74%，归母净利润-5591.11万元，同比下降11.7%。按单季度数据看，第二 季度营业总收入4411.32万元，同比上升15.05%，第二季度归母净利润-3316.77万元，同比下降57.27%。 本报告期康为世纪公司应收账款体量较大，当期应收账款占最新年报营业总收入比达47.18%。 本次财报公布的各项数据指标表现一般。其中，毛利率51.69%，同比减19.74%，净利率-64.73%，同比 增13.08%，销售费用、管理费用、财务费用总计7052.32万元，三费占营收比80.95%，同比减10.4%，每 股净资产12.53元，同比减11.64%，每股经营性现金流-0.44元，同比增16.15%，每股收益-0.51元，同比 减13.33% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 6714.66万 | 8711.87万 | 29.74% | | 归母净利润(元) | ...

本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司(下称"公司")第二届监事会第十四次会议于 席陈胜兰主持。 本次会议的召集、召开符合《中华人民共和国公司法》等法律法规以及《公司章程》 的相关规定，会议决议合法、有效。 证券代码：688426 证券简称：康为世纪 公告编号：2025-034 江苏康为世纪生物科技股份有限公司 一、审议通过《关于<2025 年半年度报告>及其摘要的议案》 监事会认为：公司《2025 年半年度报告》及其摘要的编制和审议程序符合相关法律 法规及《公司章程》等内部规章制度的规定，内容与格式符合《公开发行证券的公司信 息披露内容与格式准则第 3 号—半年度报告的内容与格式（2021 年修订）》、《公开发行 证券的公司信息披露编报规则第 15 号——财务报告的一般规定（2023 年修订）》等有关 文件的要求，真实、准确、完整地反映了公司 2025 年上半年的财务状况和经营成果等 事项，不存在任何虚假记载、误导性陈述或重大遗漏。 规定，对募集资金进行了专户存储和专项使用，及时履 ...

证券代码：688426 证券简称：康为世纪 公告编号：2025-033 江苏康为世纪生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东大会召开日期：2025年9月15日 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 （一） 股东大会类型和届次 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 15 日 14 点 40 分 召开地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世纪生物科技股 份有限公司 2 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 二、 会议审议事项 本次股东大会审议议案及投票股东类型 投票股东类型 序号 议案名称 网络投票起止时间：自2025 年 9 月 15 日 至2025 年 9 月 15 日 采用上海证 ...

证券代码：688426 证券简称：康为世纪 公告编号：2025-030 事会第十四次会议审议，通过了《关于 2024 年限制性股票激励计划第一个归属 期不符合归属条件暨作废已授予尚未归属的限制性股票的议案》，同意对 2024 年限制性股票激励计划中已获授但尚未归属的第二类限制性股票 2,098,400 股全 部取消归属，并作废失效。 江苏康为世纪生物科技股份有限公司 关于 2024 年限制性股票激励计划第一个归属期不符合 归属条件暨作废已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开的第二届董事会第十六次会议和第二届监事会第十四次会议审议通过了 《关于 2024 年限制性股票激励计划第一个归属期不符合归属条件暨作废已授予 尚未归属的限制性股票的议案》，同意对 2024 年限制性股票激励计划中已获授但 尚未归属的第二类限制性股票 2,098,400 股全部取消归属，并作废失效。其中 失去了激励资格须予以作 ...

Core Viewpoint - Jiangsu Cowin Biotech Co., Ltd. reported a significant increase in revenue for the first half of 2025, with total revenue reaching approximately 87.12 million yuan, a 29.74% increase compared to the same period last year. However, the company also experienced a net loss of approximately 55.91 million yuan, which is an 11.70% increase in losses compared to the previous year [5]. Company Overview - Jiangsu Cowin Biotech Co., Ltd. specializes in molecular detection technology and has over ten years of research and development experience in core technologies related to molecular detection [6]. - The company has developed over 700 core products, including molecular detection raw enzymes, nucleic acid preservation reagents, nucleic acid extraction and purification reagents, and molecular diagnostic kits [6][9]. - The company holds 74 domestic medical device registration or filing certificates and has obtained overseas medical device registrations for 70 products, establishing a comprehensive product system [6]. Financial Performance - For the first half of 2025, the company reported total revenue of 87,118,671.74 yuan, compared to 67,146,615.25 yuan in the same period last year, marking a 29.74% increase [5]. - The total profit for the period was -60,630,052.93 yuan, slightly worse than the -57,766,203.41 yuan reported in the previous year, indicating a 4.96% increase in losses [5]. - The net profit attributable to shareholders was -55,911,138.36 yuan, compared to -50,056,858.08 yuan in the previous year, reflecting an 11.70% increase in losses [5]. Research and Development - The company has established seven technical platforms and 32 core technologies related to molecular detection, and has been granted 33 domestic invention patents and 61 utility model patents [6]. - The company focuses on the research and development of molecular detection raw enzymes, having developed 186 types of enzymes that are widely applicable in various molecular biology experiments [6][9]. Product Development - The company has launched innovative products in the gastrointestinal and respiratory disease screening and diagnosis fields, including a series of nucleic acid detection kits for Helicobacter pylori, which is a significant risk factor for gastric cancer [9]. - The company has developed nucleic acid preservation reagents that are crucial for molecular detection, with over 70 types of products available, ensuring comprehensive sample collection and preservation capabilities [6][9].

江苏康为世纪生物科技股份有限公司2025 年半年度报告摘要 公司代码：688426 公司简称：康为世纪 规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 江苏康为世纪生物科技股份有限公司 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生重大不利 影响的风险因素，敬请投资者注意投资风险。 江苏康为世纪生物科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 公司股票简况 | 股票种类 | 股票上市交易所 股票简称 | | 股票代码 | 变更前股票简称 | | | --- | --- | --- | --- | --- | --- | | A股 | 上海证券交易所科创板 康为世纪 | | 688426 | 不适用 | | | 公司存托凭证简况 | | | | | | | □适用 √不适用 | | | | | | | 联系人和联系方式 | | | | | | | 联系人和 | | | | | | | | 董事会秘书（信息披露境内代表） | | 证券事务代表 | | | ...

第五章 回避制度 第一章 总则 第二章 薪酬与考核委员会 董事会对薪酬与考核委员会的建议未采纳或者未完全采纳的, 应当在董事会 决议中记载薪酬与考核委员会的意见及未采纳的具体理由, 并进行披露。 第一条 为保证公司规范经营, 建立有效的监督机制和激励机制, 进一步建立健全公 司董事(非独立董事)及高级管理人员的考核和薪酬管理制度, 完善公司治理结 构, 根据《中华人民共和国公司法》(以下简称"《公司法》")、《上市公司 治理准则》《上市公司独立董事管理办法》等有关法律、法规、规章、规范 性文件和《江苏康为世纪生物科技股份有限公司章程》(以下简称"公司章程") 的规定, 结合公司实际情况, 制定本工作细则。 第二条 董事会薪酬与考核委员会是董事会依据相应法律法规设立的专门工作机构, 主要负责制定公司董事及高级管理人员的考核标准并进行考核; 负责制定、审 查公司董事及高级管理人员的薪酬决定机制、决策流程、支付与止付追索安 排等薪酬政策与方案, 对董事会负责。 第三条 本工作细则所称董事是指在本公司支取薪酬的董事长、董事, 高级管理人员是 指董事会聘任的总经理、副总经理、财务总监和董事会秘书等其他高级管理 人员。 ...

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance company quality, stabilize the capital market, and support high-quality economic development [2] Group 1: Business Focus and Core Competitiveness - The company focuses on its main business, enhancing customer satisfaction and increasing R&D investment to improve market competitiveness and technological leadership [2] - The company has over ten years of R&D experience in molecular detection core technologies, making it one of the few domestic biotech firms with a complete business layout in this area [2] - The company has expanded its business into the screening and diagnosis of gastrointestinal diseases and respiratory infectious diseases, developing several innovative products and services [2][3] Group 2: Technological Advancements - The company has established a nanopore sequencing platform, which offers advantages such as ultra-long read lengths, compact and flexible equipment, and short sequencing times [3] - The nanopore sequencing technology has significant application potential in research, breeding, and pharmaceuticals [3] Group 3: Financial Performance - The company reported a total profit of -60.63 million yuan, a year-on-year decrease of 4.96%, and a net profit attributable to the parent company of -55.91 million yuan, down 11.70% year-on-year [3] Group 4: Marketing and Sales Strategy - The company has established 11 domestic sales regions and 2 international sales regions, with marketing offices in 12 cities, enhancing product promotion and market coverage [4] - A CRM system has been implemented to strengthen customer relationships and improve customer satisfaction and loyalty [5] Group 5: R&D and Innovation - The company has obtained multiple medical device registrations and patents, with ongoing R&D projects progressing steadily [6] - R&D expenses for the first half of 2025 amounted to 40.81 million yuan, a decrease of 11.32% year-on-year [5] Group 6: Operational Management - The company has improved operational efficiency through refined management practices across sales, R&D, production, and management [10] - Key performance indicators have been established to monitor production, material management, and customer support [12] Group 7: Corporate Governance and Investor Relations - The company emphasizes the importance of corporate governance and internal control systems to protect shareholder rights [13] - A stock incentive plan has been introduced to align the interests of shareholders and employees, involving 182 individuals [14] Group 8: Shareholder Returns - Due to negative net profits, the company does not meet the conditions for profit distribution but plans to use part of the raised funds for share repurchase to enhance investor confidence [15][16]

Core Viewpoint - The announcement details the expected daily related transactions for Jiangsu Kangwei Century Biotechnology Co., Ltd. in 2025, emphasizing that these transactions are necessary for normal business operations and will not adversely affect the company's ongoing viability or independence [1][8]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2025 during meetings held on August 27, 2025, with non-related directors and all supervisors voting in favor [1]. - The transactions are based on normal production and operational needs, adhering to fair and equitable pricing principles [1][7]. Group 2: Expected Amounts and Categories - The expected transaction amounts for 2025 include purchasing raw materials for 15 million yuan and providing labor services for 2 billion yuan [3][4]. - The total expected amount for related transactions is 2.84 billion yuan, with specific categories including vehicle leasing, office space leasing, property management, and technical services [4][6]. Group 3: Related Parties and Relationships - The related parties include Shanghai Tianhao Biotechnology Co., Ltd., which holds a 49% stake in a subsidiary, and Beijing Kangwei, the controlling shareholder of the company [5][6]. - The company maintains a stable cooperative relationship with these related parties, ensuring ongoing transactions [8]. Group 4: Pricing Policies and Agreements - The pricing for related transactions is determined based on market principles, ensuring fairness and non-detriment to the company and its shareholders [7]. - Contracts or agreements will be signed with related parties based on the specific business needs following board approval [7][8]. Group 5: Necessity and Impact of Related Transactions - The expected related transactions are deemed necessary for the company's stable operations and business development, enhancing market competitiveness [7][8]. - The company asserts that these transactions will not lead to dependency on related parties and will not harm the interests of shareholders, particularly minority shareholders [7][8].